… reported the following fourth quarter results for the … Fourth Quarter Segment Sales Analysis (Change Over Prior Year)   Pharma … exchange rates. The fourth quarter reported effective tax … from Investing Activities:       Capital expenditures   (270,419 )     (276 …

… in the fourth quarter of 2025, compared to the fourth quarter 2024 … .5 million in MRD pharma regulatory milestone revenue in … both the fourth quarter of 2025 and the fourth quarter of the … does not reflect: all expenditures or future requirements for capital …

SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned …

… finished 2025 with solid fourth quarter financial results, delivering full … portion), EnlivenHealth, Specialty Pharmacy Services, 340B solutions, … fiscal year and fourth quarter 2025 financial results. … account certain capital expenditures and cash used …

… for fourth quarter 2025 increased 16% relative to fourth quarter 2024, … to 2024. For Pharmacy Benefit Services: Fourth quarter 2025 and full … fourth quarter 2025, compared to 87.9% for fourth quarter 2024 … ~$9,000 Capital Expenditures2 ~$1,300 Shareholder Dividends2 …

… Inc. (NYSE:SLGN) Q4 2025 Earnings Call Transcript February … tax rate in the fourth quarter. The fourth quarter tax rate was … functioning, your position in pharmaceuticals and health care and so … know, our two largest expenditures that we have and critically …

… the fiscal year and fourth quarter of 2025, reporting GAAP … ’s fiscal year and fourth quarter of 2025 financial results. … services, long-term care pharmacy and other consulting services … current revenues or cash expenditures. A material limitation associated …

… and shareholder value.” Fourth quarter 2025 total company … by tariff expense. Fourth quarter 2025 segment financial performance … Patient Care Solutions Pharmaceutical Diagnostics Segment Revenues … 72%. Capital expenditures (2) in the fourth quarter of $134 …

… operating expenses.For the fourth quarter, non-GAAP operating … collections and higher capital expenditures, partially offset by business … $Millions, except percentages Q4 '25 Q4 '24 YOY … A randomized, double-blind pharmacokinetic similarity study of ABP …

… Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter … GAAP SG&A expenditure between $2.5 … of Regeneron. Regeneron Pharmaceuticals shares gained 2.1% … price targets on Regeneron Pharmaceuticals following earnings announcement. …